重组生物技术类药物不良反应研究进展  

Review of Adverse Reactions of Recombinant Biological Drugs

作　　者：张林[1] 周云 任亚萍 徐雯宇[1] 丁洁卫[1] ZHANG Lin;ZHOU Yun;REN Yaping;XU Wenyu;DING Jiewei(Department of Pharmacy,Shaoxing People＇s Hospital,Shaoxing Hospital of Zhejiang University,Shaoxing 312000,China;Renji College,Wenzhou Medical University,Wenzhou 325035,China)

机构地区：[1]绍兴市人民医院浙江大学绍兴医院药学部,绍兴312000 [2]温州医科大学仁济学院,温州325035

出　　处：《医药导报》2018年第8期977-981,共5页Herald of Medicine

基　　金：浙江省科技厅公益性科研项目(2015C33285);绍兴市公益性计划应用研究项目(2015B70070)

摘　　要：随着重组细胞因子类生物制剂药物的大量应用,其不良反应报道日渐增多。笔者通过检索几类如重组人干扰素、重组人粒细胞刺激因子、重组人白细胞介素和重组人促红素等重组细胞因子类药物不良反应的文献,了解该类药物不良反应发生的特点,并分析发生的原因,为临床的安全用药提供参考。With the extensive use of recombinant cytokine biologic drugs in hospitals,the reports of adverse reactions of such drugs are also increasing. In this paper,by searching adverse effects of several types of recombinant human interleukin,such as recombinant human granulocyte stimulating factor,recombinant human interleukin,recombinant human interleukin,and other recombinant cytokines through database,we may understand the rules and the occurrence characteristics of adverse drug reaction of these,in-depth analysis of the causes of adverse reactions,and provide a good reference for the clinical application of such drugs safely.

关 键 词：重组人干扰素 重组人粒细胞刺激因子 重组人白细胞介素 重组人促红素 不良反应 

分 类 号：R915[医药卫生—微生物与生化药学] R969.3[医药卫生—药学]